Late filing
high
Filing comparison
CASI Pharmaceuticals, Inc. told the SEC it could not file its annual report on time
(the “Company”) is unable, without unreasonable effort or expense, to file its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 (the “Form 20-F”) within the prescribed period because U.S. GAAP financial statements of the Company are not yet available. The Company expects to file its Form 20-F once the financial statements for inclusion therein become available. Based on currently available information, management anticipates it will disclose, in the Form 20-F, that there remains substantial doubt about the Company’s ability to continue as a going concern.
Evidence
- Days past due date
- 21
- Routine
- No
- Severity
- high
- Source
- Form 12b-25 (notification of late filing)
- Stated reason
- (the “Company”) is unable, without unreasonable effort or expense, to file its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 (the “Form 20-F”) within the prescribed period because U.S. GAAP financial statements of the Company are not yet available. The Company expects to file its Form 20-F once the financial statements for inclusion therein become available. Based on currently available information, management anticipates it will disclose, in the Form 20-F, that there remains substantial doubt about the Company’s ability to continue as a going concern.
- Why
- The company told the SEC it could not file a periodic report on time, using Form 12b-25.